Articles

admin

Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG

GLM101 is the first disease-modifying therapeutic in development to treat PMM2-CDG, the most common congenital disorder of glycosylation Data from the ongoing Phase 2 open-label study of GLM101 provide clinical proof of concept, showing improvement in ataxia, a key burden of disease in PMM2-CDG Funding will support advancement of GLM101 into a randomized, placebo-controlled Phase…

View details
Results from NEXUS interim analysis published in eClinicalMedicine, part of THE LANCET DiscoveryScience

2025-06-05 We are pleased to announce that the results from the positive 24w NEXUS interim analysis conducted in 2023 have been published in a manuscript entitled “Safety and efficacy of leriglitazone in childhood cerebral adrenoleukodystrophy (NEXUS): an interim analysis of an open-label, phase 2/3 trial” in eClinicalMedicine, part of THE LANCET DiscoveryScience (https://doi.org/10.1016/j.eclinm.2025.103265). We would…

View details
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants…

View details
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the Appointment of Tony Gibney as Chief Financial and Business Officer BOSTON, May 15, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors…

View details
Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON, May 01, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference on Thursday, May 8, 2025.Fireside Chat at 9:30 a.m. ET. H.C. Wainwright 3rd Annual BioConnect Investor Conference at…

View details
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company’s Board of Directors, effective March 31, 2025. “I am pleased to welcome Teresa to our…

View details
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential Clinical Pipeline Continues to Advance with Phase 3 CoMpass Trial Actively Enrolling Phase 2 Trial in Metastases to the Choroid Initiated Cash Position Expected to Support Operations into 2H 2026 BOSTON, Mass., March…

View details
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect Favorable Safety Profile; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients Data Supports Potential for a Paradigm Shifting Approach in the Front-Line Treatment of patients with NMIBC…

View details
Glycomine Appoints Joshua Grass as Chairperson of Board of Directors

October 10, 2024 SAN CARLOS, Calif., October 10, 2024 – Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for serious unserved orphan diseases, today announced the appointment of Joshua Grass as Chairperson of the Board. Mr. Grass succeeds Christopher Starr, Ph.D., who will continue to support the company as a scientific and clinical…

View details